NCT04485546View on ClinicalTrials.gov

Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis

PHASE4CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

September 9, 2020

Primary Completion Date

September 30, 2021

Study Completion Date

March 30, 2022

Conditions
Neurotrophic Keratitis
Interventions
DRUG

cenegermin-bkbj

Cenegermin-bkbj ophthalmic solution administered as one drop in affected eye(s) every 2 hours 6 times daily for 8 weeks

Trial Locations (5)

19104

Philadelphia, Philadelphia

41017

Edgewood, Edgewood

63131

Saint Louis, St Louis

92122

San Diego, San Diego

02111

Boston, Boston

Sponsors

Collaborators (1)

Dompé US
All Listed Sponsors
collaborator

Dompé US

UNKNOWN

lead

Dompé Farmaceutici S.p.A

INDUSTRY

NCT04485546 - Study to Evaluate OXERVATE™ in Patients With Stage 1 Neurotrophic Keratitis | Biotech Hunter | Biotech Hunter